Have a personal or library account? Click to login
The influence of montelukast on the autonomic nervous system activity in rats with cyclophosphamide-induced hemorrhagic cystitis Cover

The influence of montelukast on the autonomic nervous system activity in rats with cyclophosphamide-induced hemorrhagic cystitis

Open Access
|Nov 2015

References

  1. 1. Altayli E. et al.: Prevention and treatment of cyclophosphamide and ifosfamide-induced hemorrhagic cystitis. J. Mol. Pathophysiol., 1, 53, 2012.10.5455/jmp.20120321060902
  2. 2. Benarroch E.E.: Autonomic-mediated immunomodulation and potential clinical relevance. Neurology, 73, 236, 2009.10.1212/WNL.0b013e3181aebd43
  3. 3. Bouchelouche K. et al.: Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis. J. Urol., 166, 2121, 2001.10.1016/S0022-5347(05)65518-8
  4. 4. Bouchelouche K. et al.: The action of cysteinyl-leukotrienes on intracelluar calcium mobilization in human detrusor myocytes. BJU Int., 87, 690, 2001.10.1046/j.1464-410x.2001.02135.x
  5. 5. Bouchelouche K. et al.: The cysteinyl leukotriene D4 receptor antagonist montelukast fort the treatment of interstitial cystitis. J. Urol., 166, 1734, 2001.10.1016/S0022-5347(05)65663-7
  6. 6. Chuang Y.C. et al.: Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and supresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol., 56, 159, 2009.10.1016/j.eururo.2008.05.00718514386
  7. 7. Dobrek Ł., Baranowska A., Thor P.J.: The inf luence of oxazaphosphorines alkylating agents on autonomic nervous system activity in rat experimental cystitis model. Acta Pol. Pharm., 70, 1097, 2013.
  8. 8. Dobrek Ł., Thor P.: Heart rate variability in overactive bladder experimental model. Arch. Med. Sci., 9, 930, 2013.
  9. 9. Dobrek Ł., Thor P.J.: Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and ist chemoprevention. Postepy Hig. Med. Dosw. (online), 66, 592, 2012.
  10. 10. Girard B.M. et al.: Increased expression of interleukin-6 family members and receptors in urinary bladder with cyclophosphamideinduced bladder inflammation in female rats. Front. Neurosci., 5, article 20, 2011.10.3389/fnins.2011.00020304455921373362
  11. 11. Goncalves H. et al.: Analysis of heart rate variability in a rat model of induced pulmonary hypertension. Med. Eng. Phys., 32, 746, 2010.10.1016/j.medengphy.2010.04.01820547091
  12. 12. Grover S. et al.: Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol., 3, 19, 2011.10.1177/1756287211398255312608821789096
  13. 13. Haeggstrom J.Z., Funk C.D.: Lipooxygenase and leukotriene pathways: biochemistry, biology and roles in disease. Chem. Rev., 111, 5866, 2011.
  14. 14. Huston J.M., Tracey K.J.: The pulse of inflammation: heart rate variability, the cholinergic anti-inf lammatory pathway and implications for therapy. J. Intern. Med., 269, 45, 2011.
  15. 15. Karim N, Hasan JA, Ali SS. Heart rate variability - a review. J. Basic Appl. Sci., 7, 71, 2011.
  16. 16. Lampert R. et al. : Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am. Heart J., 156, 759e1, 2008.10.1016/j.ahj.2008.07.009258793218926158
  17. 17. Lanza,G.A. et al.: Relation of heart rate variability to serum levels of C reactive protein in patients with unstable angina pectoris. Am. J. Cardiol., 97,1702, 2006.
  18. 18. Lee G., Romih R., Zupancic D.: Cystitis: from urothelial cell biology to clinical application. Biomed. Res. Int., article ID 473536, 2014.10.1155/2014/473536402211324877098
  19. 19. Mohamadin A.M. et al.: Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver. Pathophysiology, 18, 235, 2011.
  20. 20. Mukherjee N. et al.: Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice. PLoS ONE, 8, e61607, 2013.10.1371/journal.pone.0061607363401923626702
  21. 21. Nicolini A. et al.: Malnutrition, anorexia and cachexia in cancer patients: a mini review on pathogenesis and treatment. Biomed. Pharmacother., 67, 807, 2013.
  22. 22. No Authors listed. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Eur. Heart J., 17, 354, 1996.
  23. 23. Papaioannou V., Pneumatikos I., Maglaveras N.: Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations. Front. Physiol., 4, 174, 2013.
  24. 24. Rahnama’i M.S., van Koevringe G.A., van Kerrebroeck P.E.: Overactive bladder symptom and the potential role of prostaglandins and phosphodiesterases: an introduction. Nephro. Urol. Mon., 5, 933, 2013.
  25. 25. Sztajzel J.: Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. Swiss. Med. Wkly. 134, 514, 2004.
  26. 26. Tintinger G.R. et al.: Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal, 10, 2403, 2010.10.1100/tsw.2010.229576394121170491
  27. 27. Traut J.L. et al.: Montelukast for symptom control of interstitial cystitis. Ann. Pharmacother., 45, e49, 2011.10.1345/aph.1Q13021862713
  28. 28. Zeng J. et al.: Cause of residual urine in bladder outlet obstruction: an experimental study in the rat. J. Urol., 188, 1027, 2012. 10.1016/j.juro.2012.04.10122819110
DOI: https://doi.org/10.1515/cipms-2015-0066 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 170 - 175
Submitted on: Jul 6, 2015
|
Accepted on: Aug 21, 2015
|
Published on: Nov 26, 2015
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Lukasz Dobrek, Beata Skowron, Agnieszka Baranowska, Piotr Jan Thor, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.